MedKoo Cat#: 140245 | Name: Rezatapopt
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Rezatapopt, also known as PC14586, is p53 Y220C reactivator that binds selectively to p53 Y220C mutant protein and restores the p53 wildtype conformation and transcriptional activity, resulting in potent preclinical antitumor activity. PC14586 was structurally designed to bind tightly to a crevice within the mutant protein (KD~2.5 nM). PC14586 was shown to stabilize the Y220C mutant in the wild type conformation, resulting in reactivation of p53 transcriptional activity and subsequent expression of its target proteins (e.g. p21, MDM2, Bax, PUMA). The reactivation of p53 function is highly selective to Y220C mutant cells and results in arrest of the cell cycle in vitro (IC50 ~0.230-1.8 μM). In nude mice bearing Y220C mutant NUGC3 gastric cancer xenograft tumors, oral administration of PC14586 results in a dose responsive anti-tumor effect. In human xenografts, PC14586 was shown to convert Y220C mutant to the wildtype conformation, resulting in activation of p53 transcription.

Chemical Structure

Rezatapopt
Rezatapopt
CAS#2636846-41-6

Theoretical Analysis

MedKoo Cat#: 140245

Name: Rezatapopt

CAS#: 2636846-41-6

Chemical Formula: C28H31F4N5O2

Exact Mass: 545.2414

Molecular Weight: 545.58

Elemental Analysis: C, 61.64; H, 5.73; F, 13.93; N, 12.84; O, 5.86

Price and Availability

Size Price Availability Quantity
5mg USD 150.00 Ready to Ship
10mg USD 250.00 Ready to Ship
25mg USD 450.00 Ready to Ship
50mg USD 750.00 Ready to Ship
100mg USD 1,350.00 Ready to Ship
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Rezatapopt; PC14586; PC-14586; PC 14586;
IUPAC/Chemical Name
4-({3-[4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)-3-methoxy-N-methylbenzamide
InChi Key
NKRKBSQLUPEVCZ-JTHBVZDNSA-N
InChi Code
InChI=1S/C28H31F4N5O2/c1-33-27(38)18-9-10-24(26(14-18)39-3)34-12-5-6-19-15-20-22(35-23-11-13-36(2)16-21(23)29)7-4-8-25(20)37(19)17-28(30,31)32/h4,7-10,14-15,21,23,34-35H,11-13,16-17H2,1-3H3,(H,33,38)/t21-,23+/m0/s1
SMILES Code
O=C(NC)C1=CC=C(NCC#CC(N2CC(F)(F)F)=CC3=C2C=CC=C3N[C@H]4[C@@H](F)CN(C)CC4)C(OC)=C1
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
The p53 tumor suppressor protein is a transcription factor that acts to maintain genome stability in response to cellular stress. Spontaneous mutation of the TP53 gene leading to inactivation of the p53 protein is the most common mutational event across all human cancers.
Biological target:
The biological target of rezatapopt is the TP53 Y220C mutation.
In vitro activity:
In vivo activity:
In this study, mouse models with established human tumor xenografts carrying the TP53 Y220C mutation were used to evaluate the efficacy of rezatapopt. The drug demonstrated significant tumor inhibition and regression in these mice at well-tolerated doses, suggesting its potential to target and reactivate the mutant p53 protein. Vu BT, Dominique R, Fahr BJ, Li HH, Fry DC, Xu L, Yang H, Puzio-Kuter A, Good A, Liu B, Huang KS, Tanaka N, Davis TW, Dumble ML. Discovery of Rezatapopt (PC14586), a First-in-Class, Small-Molecule Reactivator of p53 Y220C Mutant in Development. ACS Med Chem Lett. 2024 Nov 4;16(1):34-39.
Solvent mg/mL mM
Solubility
DMSO 100.0 183.29
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 545.58 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
Vu BT, Dominique R, Fahr BJ, Li HH, Fry DC, Xu L, Yang H, Puzio-Kuter A, Good A, Liu B, Huang KS, Tanaka N, Davis TW, Dumble ML. Discovery of Rezatapopt (PC14586), a First-in-Class, Small-Molecule Reactivator of p53 Y220C Mutant in Development. ACS Med Chem Lett. 2024 Nov 4;16(1):34-39. doi: 10.1021/acsmedchemlett.4c00379. PMID: 39811143; PMCID: PMC11726359.
In vitro protocol:
In vivo protocol:
Vu BT, Dominique R, Fahr BJ, Li HH, Fry DC, Xu L, Yang H, Puzio-Kuter A, Good A, Liu B, Huang KS, Tanaka N, Davis TW, Dumble ML. Discovery of Rezatapopt (PC14586), a First-in-Class, Small-Molecule Reactivator of p53 Y220C Mutant in Development. ACS Med Chem Lett. 2024 Nov 4;16(1):34-39. doi: 10.1021/acsmedchemlett.4c00379. PMID: 39811143; PMCID: PMC11726359.
[1]. Li Sujing, et al. Heteroarylalkyne compounds for targeting mutant of p53 and their preparation. World Intellectual Property Organization, WO2023016434 A1. 2023-02-16. https://www.freepatentsonline.com/WO2023016434.html